Charles River Laboratories International (NYSE:CRL – Get Free Report) will likely be posting its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of $2.74 per share and revenue of $977.1980 million for the quarter. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 9:00 AM ET.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. During the same quarter in the prior year, the business posted $2.34 EPS. The business’s revenue was up 1.2% compared to the same quarter last year. On average, analysts expect Charles River Laboratories International to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.
Charles River Laboratories International Stock Down 0.8%
Shares of CRL opened at $230.58 on Tuesday. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. Charles River Laboratories International has a 12 month low of $144.26 and a 12 month high of $242.73. The firm’s 50 day moving average is $207.99 and its 200-day moving average is $188.00. The stock has a market capitalization of $11.11 billion, a PE ratio of -61.33, a P/E/G ratio of 2.59 and a beta of 1.38.
Insiders Place Their Bets
Hedge Funds Weigh In On Charles River Laboratories International
A number of institutional investors have recently modified their holdings of the business. Mercer Global Advisors Inc. ADV boosted its stake in Charles River Laboratories International by 1.3% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock worth $1,260,000 after purchasing an additional 80 shares in the last quarter. Advisory Services Network LLC increased its stake in Charles River Laboratories International by 2.6% during the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock valued at $505,000 after purchasing an additional 83 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Charles River Laboratories International by 14.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 744 shares of the medical research company’s stock worth $150,000 after buying an additional 94 shares during the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of Charles River Laboratories International by 0.6% in the third quarter. Public Employees Retirement System of Ohio now owns 15,240 shares of the medical research company’s stock worth $2,384,000 after buying an additional 95 shares during the last quarter. Finally, Brown Advisory Inc. lifted its stake in shares of Charles River Laboratories International by 5.1% during the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after buying an additional 114 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.
Wall Street Analyst Weigh In
CRL has been the topic of a number of recent research reports. CLSA lowered Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective on the stock. in a research note on Monday, July 20th. Barclays upped their target price on Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Citigroup restated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a research report on Wednesday, July 1st. Finally, Morgan Stanley boosted their price target on Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $220.75.
Get Our Latest Stock Report on Charles River Laboratories International
About Charles River Laboratories International
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Featured Stories
- Five stocks we like better than Charles River Laboratories International
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
